pharmaceutical investing Algernon Submits for Ethics Approval in Australia for Multinational Phase 2b/3 Human Study of Ifenprodil for COVID-19
pharmaceutical investing Algernon Receives First Ethics Approval for Phase 2 Ifenprodil IPF and Chronic Cough Human Study in Australia
pharmaceutical investing Algernon Pharmaceuticals Announces up to $5.0 Million Private Placement Offering of Special Warrants
Algernon Receives Clearance from Health Canada for Ifenprodil COVID-19 Phase 2b/3 Multinational Clinical Trial
pharmaceutical investing Algernon Presents “The Science of Ifenprodil” on a Special BioPub Webcast Hosted by Dr. KSS, MD, PhD
pharmaceutical investing Algernon Receives Regulatory and Ethics Approval for Phase 2 Ifenprodil COVID-19 Human Study in South Korea
pharmaceutical investing Algernon Submits Application to Health Canada for Ifenprodil COVID-19 Phase 2b/3 Multinational Clinical Trial
pharmaceutical investing Algernon Receives Positive Feedback from U.S. FDA for New Ifenprodil Intravenous Formulation
pharmaceutical investing Algernon Receives Positive Feedback from U.S. FDA for Ifenprodil COVID-19 Human Trial; Appoints U.S. Ambassador (Rtd) Howard Gutman to Advisory Board
pharmaceutical investing Algernon Announces Regulatory Submission for Ifenprodil COVID-19 Human Trial in South Korea
pharmaceutical investing Algernon Announces Positive Feedback from Health Canada for Ifenprodil COVID-19 Phase 2 Human Trial
pharmaceutical investing Algernon Provides Update on Phase 2 Human Testing of Ifenprodil for COVID-19
pharmaceutical investing Algernon Submits for Ethics Approval for Phase 2 IPF and Chronic Cough Study
pharmaceutical investing Algernon Provides an Overview of its NP-120 (Ifenprodil) Program for COVID-19
